chevron_leftBack
As of 24 April 2025, LungLife AI, Inc. has a market cap of $917.5K USD, ranking #38901 globally and #5570 in the United States. It ranks #3947 in the Healthcare sector, and #212 in the Diagnostics & Research industry.
Key Stats
Market Cap
$917.5KUSD
689.82K GBP
Enterprise Value
-$1.62MUSD
-1.22M GBP
Revenue (TTM)
$30.52KUSD
22.95K GBP
EBITDA (TTM)
-$4.59MUSD
-3.45M GBP
Net Income (TTM)
-$4.7MUSD
-3.53M GBP
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Paul Pagano
open_in_new
Employees
15
Founded
2009
Website
lunglifeai.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -63% | 27% | 27% | -63% | -63% | -77% |
Upcoming Earnings
Earnings Date
Thu, May 22
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
LLA
LungLife AI Inc Ordinary Shares - Reg S
ISIN: USU5500L1128
Shares Out.:
Shares Outstanding:
25.486M1
Shares Float:
25.462M2
|
6 GBX | |
|
LLAI
LungLife AI Inc
ISIN: USU5500L1045
|
2 GBX |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About LungLife AI, Inc.
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People’s Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. LungLife AI, Inc. was incorporated in 2009 and is based in Thousand Oaks, California.
